Minnie Mc Millan, PhD

Dr. Minnie McMillan is a Founder of Anergix and member of the Anergix Advisory Board. She is a molecular immunogeneticist and a Professor of Microbiology and Neurology at USC. She obtained B.A., B.Sc. and D.Phil. degrees in Chemistry from Oxford University, England, where she was an Exhibitioner at Somerville College. After emigrating to the United States, she became a Gosney Fellow in Biology in the laboratory of Lee Hood at the California Institute of Technology. She then moved to USC, now the Keck School of Medicine, where she is presently a Professor. Her research focuses on the major histocompatibility complex and its role in autoimmunity, particularly, multiple sclerosis. She has been awarded numerous grants from NIAID and NIGMS and has chaired as well as served on many NIH and NCI review panels.

• The signal peptide sequence impacts the immune response elicited by a DNA epitope vaccine Clin Vaccine Immunol. 2011 Oct; 18(10):1776-80. . View in PubMed
• CD4+ T cell epitope affinity to MHC II influences the magnitude of CTL responses elicited by DNA epitope vaccines Vaccine. 2005 Apr 08; 23(20):2639-46. . View in PubMed
• Gene therapy in a murine model for clinical application to multiple sclerosis Ann Neurol. 2004 Mar; 55(3):390-9. . View in PubMed
• Caprine arthritis-encephalitis virus-infected goats can generate human immunodeficiency virus-gp120 cross-reactive antibodies(1) Virology. 2003 Oct 10; 315(1):217-23. . View in PubMed

• Kast, Wijbe